Scinai Immunotherapeutics (SCNI) Study Update summary

Unmet need in plaque psoriasis

• Plaque psoriasis affects 2-3% of the global population, with one-third experiencing moderate to severe disease.

• Current biologics and small molecules leave gaps for patients with mild to moderate disease, especially in hard-to-treat areas.

• Local treatments like corticosteroids have adverse effects and limitations, while systemic biologics are not suitable for localized lesions.

Role of IL-17 and rationale for dual targeting

• IL-17A and IL-17F are key cytokines in psoriasis pathogenesis, both contributing to disease activity.

• Inhibiting both isoforms is more effective than targeting IL-17A alone, as IL-17F is present at higher concentrations in psoriatic lesions.

• Dual inhibition offers a more comprehensive approach to disease control.

VHH single domain antibodies: features and advantages

• VHH antibodies are single-chain, compact, and about 10 times smaller than conventional monoclonal antibodies.

• They are highly stable, robust, and can be produced at lower cost and larger scale.

• Their small size makes them ideal for local administration, reducing systemic exposure and potential side effects.